InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,702.55
(
-0.19%
)
US TECH 100
19,287.60
(
-0.24%
)
Dow Jones
42,063.36
(
0.09%
)
Brent Oil
74.14
(
0.00%
)
Bitcoin
63,026.96
(
-0.28%
)
Post# of 253168
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 840
Posts 120475
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: John Tucker post# 182975

Monday, 10/20/2014 1:35:36 PM

Monday, October 20, 2014 1:35:36 PM

Post# of 253168
ACHN—To keep this thread in perspective: My view is that IP protection isn’t the biggest risk for ACHN; rather, the biggest risk is that ACH-3422 simply doesn’t work as well as Sovaldi (or other HCV nukes in development).

The ACH-3422 monotherapy data to be reported at AASLD won’t tell us as much as some investors think about whether the drug ultimately succeeds or fails.

p.s. Welcome to the board!

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up